Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 163 participants.

Also called NCT02448641

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 163 participants (enrolled count) (from the registry)
Sponsor
SanBio, Inc. (from the registry)
Registry
  • NCT NCT02448641
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02448641. Randomized; double masking; primary purpose treatment. Start 2016-03-08 (actual); primary completion 2018-12-05 (actual). Results posted on 2020-04-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke
Acronym
ACTIsSIMA
Condition
Chronic Ischemic Stroke
Intervention (Biological)
SB623 Implant (2.5M)
Intervention (Biological)
SB623 Implant (5.0M)
Intervention (Procedure)
Sham surgery
Lead sponsor
SanBio, Inc. (class: industry)
Collaborator
Sumitomo Pharma America, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02448641
Content hash
e3546255b44233648e470b28290f97c50926752d38ee9e267f66de54d6c987f3